AIM: @entity0 ( @entity0 ) is considered one of the most aggressive subtypes of @entity0 . Near infrared photoimmunotherapy (NIR- @entity558 ) is a @entity5 treatment that employs an @entity9335 ( @entity9335 ) followed by exposure of NIR light for activating selective @entity137 on targeted @entity5 cells and may have application to @entity0 . In order to minimize the dose of @entity9335 while maximizing the therapeutic effects, dosing of the @entity9335 and NIR light need to be optimized. In this study, we investigate in vitro and in vivo efficacy of cetuximab (cet)-IR700 NIR- @entity558 on two @entity0 models MDAMB231 ( @entity0 , @entity12841 moderate) and MDAMB468 ( @entity0 , @entity12841 high) cell lines, and demonstrate a method to optimize the dosing @entity9335 and NIR light. METHOD: After validating in vitro cell-specific @entity137 , NIR- @entity558 therapeutic effects were investigated in @entity19 models using cell lines derived from @entity0 @entity5 . @entity5 -bearing @entity19 were separated into 4 groups for the following treatments: (1) no treatment (control); (2) 300  g of cet-IR700 i.v., ( @entity9335 i.v. only); (3) NIR light exposure only, NIR light was administered at 50 J/cm2 on day 1 and 100 J/cm2 on day 2 (NIR light only); (4) 300  g of cet-IR700 i.v., NIR light was administered at 50 J/cm2 on day 1 after injection and 100 J/cm2 of light on day 2 after injection (one shot NIR- @entity558 ). To compare different treatment regimens with a fixed dose of @entity9335 , we added the following treatments (5) 100  g of cet-IR700 i.v., NIR light administered at 50 J/cm2 on day 1 and 50  g of cet-IR700 i.v. immediately after NIR- @entity558 , then NIR light was administered at 100 J/cm2 on day 2, which were performed two times every week ("two split" NIR- @entity558 ) and (6) 100  g of cet-IR700 i.v., NIR light was administered at 50 J/cm2 on day 1 and 100 J/cm2 on day 2, which were performed three times per week ("three split" NIR- @entity558 ). RESULT: Both specific binding and NIR- @entity558 effects were greater with MDAMB468 than MDAMB231 cells in vitro. @entity5 accumulation of cet-IR700 in MDAMB468 @entity5 was significantly higher (p < 0.05) than in MDAMB231 @entity5 in vivo. @entity5 growth and survival of MDAMB231 @entity5 bearing @entity19 was significantly lower in the NIR- @entity558 treatment group (p < 0.05). In MDAMB468 bearing @entity19 , @entity5 growth and survival was significantly improved in the NIR- @entity558 treatment groups in all treatment regimens (one shot NIR- @entity558 ; p < 0.05, "two split" NIR- @entity558 ; p < 0.01, "three split" NIR- @entity558 ; p < 0.001) compared with control groups. CONCLUSION: NIR- @entity558 for @entity0 was effective regardless of expression of @entity12841 , however, greater cell killing was shown with higher @entity12841 expression @entity5 in vitro. In all treatment regimens, NIR- @entity558 suppressed @entity5 growth, resulting in significantly prolonged survival that further improved by splitting the @entity9335 dose and using repeated light exposures.

Near Infrared Photoimmunotherapy Targeting XXXX Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen.

@entity558 :: ('MESH:C536528', 'Disease') :: ['PIT'] @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'TNBC', 'Triple-negative breast cancer'] @entity12841 :: ('13649(Tax:10090)', 'Gene') :: ['EGFR'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors', 'tumor', 'cancer', 'Tumor'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity9335 :: ('MESH:D010787', 'Disease') :: ['APC', 'antibody-photosensitizer conjugate']
@entity12841 :: (13649(Tax:10090),Gene) :: ['EGFR']
